ArticleMicrobial biotechnology2022
Armeniaspirol A: a novel anti-Helicobacter pylori agent.
Article in Microbial biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Enhancing 3-O-methylfunicone production by endophytic Talaromyces pinophilus J6 through culture optimization and its anti-Helicobacter pylori activity.Archives of microbiology · 2026Article
- Isolation, Structural Elucidation, and Biological Evaluation of Pyrrole-Based Alkaloids from Sea Anemone-AssociatedMarine drugs · 2026Article
- A Comprehensive Review of Plant and Microbial Natural Compounds as Sources of PotentialBiotech (Basel (Switzerland)) · 2025Review
- In vitro anti-Helicobacter pylori activity and phenotypic screening of novel quinolone compounds.Archives of microbiology · 2025Article
- Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins AgainstMicroorganisms · 2025Article
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Review
- Molecular Mechanisms of Biofilm Formation inAntibiotics (Basel, Switzerland) · 2024Review
- Discovery of Cinnamic Acid Derivatives as Potent Anti-Molecules (Basel, Switzerland) · 2024Article
- Effect and mechanism of Qingre Huashi decoction on drug-resistantWorld journal of gastroenterology · 2024Article
- Loureirin A is a narrow-spectrum antimicrobial agent againstAntimicrobial agents and chemotherapy · 2024Article
- Development of Integrated Vectors with Strong Constitutive Promoters for High-Yield Antibiotic Production in Mangrove-DerivedMarine drugs · 2024Article
- Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections.World journal of microbiology & biotechnology · 2023Article
- Bioactive Metabolites from Terrestrial and Marine Actinomycetes.Molecules (Basel, Switzerland) · 2023Review
- Biofilm ofAntibiotics (Basel, Switzerland) · 2023Review
- Enhancing armeniaspirols production through multi-level engineering of a native Streptomyces producer.Microbial cell factories · 2023Article
- Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies forTropical medicine and infectious disease · 2023Review
- Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance fromBiomolecules · 2022Review
- Armeniaspirol A: a novel anti-Helicobacter pylori agent.Microbial biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance in Helicobacter pylori has been growing worldwide with current treatment regimens. Development of new compounds for treatment of H. pylori infections is urgently required to achieve a successful eradication therapy in the future. Armeniaspirols, a novel class of natural products isolated from Streptomyces armeniacus, have been previously identified as antibacterial agents against Gram-positive pathogens. In this study, we found that armeniaspirol A (ARM1) exhibited potent antibacterial activity against H. pylori, including multidrug-resistant strains, with MIC range values of 4-16 μg ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.